Live Breaking News & Updates on Dezima Pharma

Stay updated with breaking news from Dezima pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Form 424B3 NewAmsterdam Pharma Co

Form 424B3 NewAmsterdam Pharma Co
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Noord Holland , New South Wales , Eteläuomen Läi , Harvard University , World Health Organization , Al Qahirah , New York , Netherlands General , Republic Of China , Taiwan General , Chuo Ku , Cayman Islands , South Korea , San Francisco , District Of Columbia , Grand Cayman , Short Hills , Costa Rica , Menlo Park , State Of New York , Macau General , Hong Kong , United Kingdom , British Columbia , Russian Federation ,

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

From the ashes of CETP inhibitors emerges obicetrapib, which reduced LDL by 50%, but long-term safety data are still needed. ....

South Australia , Kausik Ray , Newamsterdam Pharma , Anne Tybj , Dezima Pharma , Stephen Nicholls , Sanofi Regeneron , Michael Davidson , John Kastelein , European Atherosclerosis Society , Md Imperial College London , Dmsc University Of Copenhagen , Phd Monash University , Imperial College London , Monash University , Age Related Macular ,

Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)

(0)
Fund launched in July 2020 invests in late-stage European life science companies
Fund now closed at the hard cap, with investors that include Pantheon, Eli Lilly and Company, Horizon Therapeutics plc (Nasdaq: HZNP), the Belgian Growth Fund, New Waves Investments, Wealth Management Partners, KfW Capital and the European Investment Fund (EIF)
First three investments made from fund
Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I ( Forbion Growth I ) at the hard cap amount of EUR 360 million (USD 428 million). Forbion Growth I is focused on investing in late-stage European life sciences companies. ....

United States , United Kingdom , Kostenloser Wertpapierhandel , Sander Slootweg , Eli Lilly , Werner Lanthaler , Tim Van Hauwermeiren , Dezima Pharma , Dirk Kersten , Moelis Co , European Recovery Programme , European Investment Fund , Belgian Growth Fund , Forbion Growth Opportunities Fundi , Advisory Group , Life Sciences , Dutch Venture Initiative , Melanie Toyne Sewell Phil Marriage Life Sciences , Horizon Therapeutics , New Waves Investments , Wealth Management Partners , Kfw Capital , Maarten De Jong , Synox Therapeutics , New Amsterdam Pharma , Gyroscope Therapeutics ,

Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)

Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Sander Slootweg , Eli Lilly , Werner Lanthaler , Tim Van Hauwermeiren , Dezima Pharma , Dirk Kersten , Moelis Co , European Recovery Programme , European Investment Fund , Belgian Growth Fund , Forbion Growth Opportunities Fundi , Advisory Group , Life Sciences , Dutch Venture Initiative , Horizon Therapeutics , New Waves Investments , Wealth Management Partners , Kfw Capital , Maarten De Jong , Synox Therapeutics , New Amsterdam Pharma , Gyroscope Therapeutics , Managing Partner , General Partner ,

NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program

NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program
NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program
NewAmsterdam Pharma (NAP), a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, today announced completion of a $196M (‚¬160M) Series A funding round.
The financing will support the full Phase 3 development of its ApoB and LDL-c lowering small molecule drug, obicetrapib. The drug, a cholesteryl ester transfer protein (CETP) inhibitor, is being developed for patients who are not well-controlled on statins.
Forbion, NAPs founding investor, was joined by Morningside Ventures and Ascendant BioCapital as co-lead investors in the Series A financing. Also participating in this funding round were Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners, LSP Dement ....

North Lanarkshire , United Kingdom , Noord Holland , Newamsterdam Pharma , Jason Dinges , Dezima Pharma , Gaurav Gupta , Michael Davidson , Peter Thiel , John Kastelein , Christopher Knospe , Dementia Fund , Population Health Partners , Mcdougall Communications , Kaiser Foundation Hospitals , Morningside Ventures , Ascendant Biocapital , Janus Henderson Investors , Amsterdam Pharma , Wide Cross Sectional Observational Study , Lipid Modifying Therapy Use , Primary Care , European Journal , Preventive Cardiology , Investor Inquiries , Dougall Communications ,